Daily Sepsis Research Analysis
Analyzed 39 papers and selected 3 impactful papers.
Summary
Analyzed 39 papers and selected 3 impactful articles.
Selected Articles
1. Conserved noncoding sequence-9 regulates NFATc1-mediated IL-10 expression in B cells to control inflammatory responses.
This study identifies a conserved enhancer (CNS-9 in mice; CNS-12 in humans) that, via NFATc1 binding and chromatin looping, drives B cell IL-10 expression. Loss of this axis reduces IL-10, heightens inflammation, and worsens survival in LPS-induced sepsis, establishing a conserved immunoregulatory pathway with therapeutic potential.
Impact: Reveals a cross-species, mechanistically defined enhancer–transcription factor pathway that governs anti-inflammatory IL-10 in B cells and influences sepsis survival.
Clinical Implications: Targeting NFATc1–enhancer interactions or enhancing B cell IL-10 could modulate hyperinflammation in sepsis and other inflammatory diseases; translational strategies may include small-molecule modulators or gene-regulatory approaches.
Key Findings
- CNS-9 acts as an NFATc1-bound enhancer that loops to the IL-10 promoter to drive transcription in mouse B cells.
- B1a cells are the predominant B cell source of IL-10, dependent on NFATc1–CNS-9 regulation.
- Deletion of CNS-9 or B cell–specific NFATc1 reduces IL-10, exacerbates inflammation, and decreases survival in LPS-induced sepsis.
- The human homologous element CNS-12 functions similarly via NFATc1-dependent mechanisms.
Methodological Strengths
- Integrative genomics defining enhancer–promoter looping with functional validation.
- Multi-system validation including mouse genetics, flow cytometry, and human homolog analysis.
Limitations
- Sepsis evidence is based on LPS-induced mouse models, which may not capture full human disease heterogeneity.
- Clinical translation to human therapeutic modulation of this axis remains untested.
Future Directions: Test pharmacologic or genetic modulation of NFATc1–enhancer activity in preclinical polymicrobial sepsis models and evaluate ex vivo human B cell modulation to inform first-in-human studies.
Interleukin-10 (IL-10) production by B cells plays a critical role in regulating inflammatory responses, yet the mechanisms controlling its expression remain poorly understood. We identified a conserved noncoding sequence (CNS-9) as an essential regulatory element for IL-10 expression in mouse B cells. Comprehensive genomic analyses revealed that CNS-9 functions as an enhancer bound by the transcription factor NFATc1, which facilitates chromatin looping between CNS-9 and the IL-10 promoter to drive transcription. Flow cytometry analyses identified B1a cells as the predominant source of B cell-derived IL-10, with this production critically dependent on NFATc1-mediated CNS-9 regulation. In a mouse model of LPS-induced sepsis, deletion of CNS-9, B cell-specific NFATc1, or both resulted in reduced IL-10 production, exacerbated inflammatory responses, and decreased survival. Furthermore, we demonstrated that the human homolog, CNS-12, functions similarly through NFATc1-dependent mechanisms. These findings establish a conserved regulatory pathway controlling IL-10 expression in B cells with notable implications for inflammatory disease pathogenesis and potential therapeutic interventions.
2. Balanced Fluid or 0.9% Saline in Children Treated for Septic Shock.
In 8,482 analyzed pediatric patients with suspected septic shock, balanced crystalloids did not reduce major adverse kidney events at 30 days compared with 0.9% saline. Electrolyte abnormalities differed, with less hyperchloremia and hypernatremia in the balanced-fluid group, but hospital-free days and safety profiles were similar.
Impact: Provides definitive, multicountry RCT evidence informing fluid choice in pediatric septic shock, clarifying that balanced crystalloids do not improve major kidney outcomes over saline.
Clinical Implications: Either balanced crystalloids or 0.9% saline are reasonable for initial resuscitation in pediatric septic shock with respect to major kidney outcomes; electrolyte profiles may guide choice (less hyperchloremia with balanced fluids).
Key Findings
- No significant difference in 30-day major adverse kidney events between balanced fluids (3.4%) and saline (3.0%).
- Hospital-free days were identical (median 23) in both groups.
- Hyperchloremia and hypernatremia were less frequent with balanced fluids than with saline.
Methodological Strengths
- Large, pragmatic multicountry RCT across 47 emergency departments.
- Pre-registered trial (NCT04102371) with clearly defined composite primary outcome.
Limitations
- Event rates for the composite kidney outcome were low (~3%), potentially limiting detection of small differences.
- Trial focused on the first 48 hours of resuscitation; longer-term fluid strategies were not assessed.
Future Directions: Evaluate subgroups (e.g., severe hyperchloremia risk, renal vulnerability) and integrate fluid composition with vasopressor and electrolyte management strategies in pediatric sepsis.
BACKGROUND: Whether treatment with balanced crystalloid fluid leads to better outcomes than 0.9% saline in children treated for septic shock is debated. METHODS: In this pragmatic clinical trial conducted at 47 emergency departments in five countries, patients (2 months to <18 years of age) with suspected septic shock and abnormal perfusion were randomly assigned to receive fluid resuscitation with either balanced fluid or 0.9% saline for up to 48 hours. The primary outcome was a major adverse kidney event (a composite of death, new renal-replacement therapy, or persistent kidney dysfunction) at 30 days after enrollment or hospital discharge, whichever occurred first. RESULTS: Of 9041 enrolled patients, 277 (6.1%) in the balanced-fluid group and 282 (6.2%) in the 0.9%-saline group withdrew from the trial, leaving 4235 and 4247 patients, respectively, for analysis. A primary-outcome event occurred in 137 patients (3.4%) in the balanced-fluid group and in 124 (3.0%) in the 0.9%-saline group (difference, 0.4 percentage points; 95% confidence interval [CI], -0.5 to 1.3; risk ratio, 1.10; 95% CI, 0.88 to 1.40; P = 0.85). The median number of hospital-free days during 28 days after enrollment was 23 (interquartile range, 19 to 25) in both groups. Hyperchloremia occurred in 868 patients (31.4%) in the balanced-fluid group and in 1383 (49.0%) in the 0.9%-saline group; hypernatremia in 52 (1.8%) and 89 (3.1%), respectively; and hyperlactatemia in 260 (19.8%) and 228 (16.7%). No differences in other safety outcomes or adverse events were seen. CONCLUSIONS: Among children treated for septic shock, no significant difference was seen in the incidence of death, new renal-replacement therapy, or persistent kidney dysfunction when fluid resuscitation was administered with balanced fluid as compared with 0.9% saline. (Funded by Eunice Kennedy Shriver National Institute of Child Health and Human Development and others; PRoMPT BOLUS ClinicalTrials.gov number, NCT04102371.).
3. HPA deficiency alleviates tissue factor expression in sepsis-induced coagulopathy by regulating HS/NLRP3 inflammasome pathway.
Patient data and mechanistic models show heparanase activation degrades glycocalyx, generates HS fragments that activate endothelial NLRP3, increase tissue factor, and worsen coagulopathy. Genetic or pharmacologic HPA inhibition preserves glycocalyx, suppresses TF/IL-1β, improves coagulation and survival in septic mice, nominating the HPA–HS–NLRP3 axis as a target.
Impact: Bridges patient biomarker data with mechanistic causality linking glycocalyx breakdown to NLRP3-driven coagulopathy, providing a concrete, druggable pathway in sepsis-induced coagulopathy.
Clinical Implications: Monitoring TF may aid SIC risk stratification (AUC 0.786). Heparanase inhibition to preserve glycocalyx and blunt HS–NLRP3 signaling emerges as a translational strategy warranting early-phase trials.
Key Findings
- Sepsis/SIC patients showed elevated serum HPA activity, HS, and TF, with TF positively correlating with HPA/HS and disease severity.
- TF predicted SIC with an AUC of 0.786.
- Genetic deletion or pharmacologic inhibition of HPA reduced HS degradation, TF expression, IL-1β release, coagulation dysfunction, and improved survival in septic mice.
- Exogenous HS activated NLRP3/caspase-1/GSDMD and upregulated TF in HUVECs; NLRP3 inhibition suppressed HS-induced TF and pyroptosis.
Methodological Strengths
- Combined human clinical biomarker analysis with in vivo genetic models and in vitro endothelial mechanistic assays.
- Convergent evidence using both genetic knockout and pharmacologic inhibition of heparanase.
Limitations
- Patient cohort size and enrollment details are not specified in the abstract.
- Reliance on LPS-induced models may limit generalizability to diverse septic phenotypes.
Future Directions: Develop selective heparanase inhibitors suitable for clinical use and test them in polymicrobial sepsis models, followed by phase I/II trials with SIC biomarker endpoints (TF, HS, IL-1β).
BACKGROUND: Heparanase (HPA) is activated in sepsis with the consequent degradation of heparan sulfate (HS) and compromising glycocalyx integrity. The NLR-family pyrin domain-containing 3 (NLRP3) inflammasome plays a critical role in initiating the coagulation cascade. Nonetheless, it remains uncertain whether HS fragments contribute to the activation of coagulation via the NLRP3 inflammasome during sepsis. METHODS: Serum concentrations of HPA, HS, and tissue factor (TF) in sepsis patients were quantified using enzyme-linked immunosorbent assay (ELISA). Mechanistic studies were conducted using wild-type and HPA-knockout C57BL/6 mice, as well as human umbilical vein endothelial cells (HUVECs). RESULTS: Patients diagnosed with sepsis or sepsis-induced coagulopathy (SIC) exhibited significantly elevated serum levels of HPA, HPA enzymatic activity, HS, and TF compared to healthy controls. A positive correlation was observed between TF levels and both HPA and HS concentrations, as well as with the severity of the disease. The area under the curve (AUC) for TF in predicting SIC was 0.786. In both in vivo sepsis models and lipopolysaccharide (LPS)-stimulated HUVECs, either genetic deletion or pharmacological inhibition of HPA attenuated HS degradation, preserved endothelial glycocalyx, reduced TF expression, suppressed the release of IL-1β, and ameliorated coagulation dysfunction. HPA deficiency also mitigated lung histopathological injury and improved survival rate in septic mice. Supplementation with exogenous HS upregulated TF expression and activated the NLRP3/caspase-1/gasdermin D (GSDMD) pathway in HUVECs. Inhibition of the NLRP3 inflammasome suppressed HS-induced TF expression and pyroptotic cell death. CONCLUSION: HPA modulates the HS/NLRP3 inflammasome pathway, which seem linked to protection against LPS-induced coagulation dysfunction. The detailed results warrant deep studies in the potential of that pathway as therapeutic target.